Diaceutics (LON:DXRX) Reaches New 12-Month High – Still a Buy?

Diaceutics PLC (LON:DXRX)’s share price hit a new 52-week high during trading on Thursday . The stock traded as high as GBX 136 ($1.69) and last traded at GBX 136 ($1.69), with a volume of 101158 shares. The stock had previously closed at GBX 125.50 ($1.56).

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on DXRX. Canaccord Genuity Group restated a “buy” rating and issued a GBX 160 ($1.99) target price on shares of Diaceutics in a report on Tuesday, December 17th. Canaccord Genuity Group reaffirmed a “buy” rating and set a GBX 160 ($1.99) price objective on shares of Diaceutics in a report on Tuesday, December 17th.

Diaceutics Stock Performance

The company’s 50-day simple moving average is GBX 120.69 and its 200 day simple moving average is GBX 126.01. The stock has a market cap of £114.03 million, a P/E ratio of -4,500.00 and a beta of 0.58. The company has a current ratio of 4.85, a quick ratio of 9.92 and a debt-to-equity ratio of 2.93.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.